Physician profile
James Bowerman
$86,924.34
in general payments reported to CMS, 2019-2025
20 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $12K · 2021: $11K · 2022: $14K · 2023: $25K · 2024: $2,250 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,157 · Travel and Lodging: $2,349 · Food and Beverage: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,410.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,157.04 |
| Travel and Lodging | $2,349.46 |
| Food and Beverage | $968.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $19,061.17 | 2019-2024 | Voxzogo 1.2mg |
| Emd Serono, INC. | $11,435.00 | 2019-2023 | |
| Genentech USA, INC. | $9,907.07 | 2020-2023 | Xolair |
| Novo Nordisk INC | $7,462.63 | 2023 | |
| Boehringer Ingelheim International Gmbh | $4,604.00 | 2019 | |
| Janssen Scientific Affairs, LLC | $4,305.78 | 2019 | |
| Roche Diagnostics Corporation | $4,041.92 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $3,560.00 | 2021 | |
| Omeros Corporation | $2,959.76 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,840.00 | 2021-2022 | |
| Novo Nordisk As | $2,520.00 | 2020 | |
| Baxter Healthcare | $2,400.00 | 2022 | |
| H. Lundbeck A S | $2,125.00 | 2021 | |
| Glaxosmithkline, LLC. | $2,000.00 | 2022 | |
| Gilead Sciences, INC. | $1,867.50 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $1,750.00 | 2019 | |
| Sage Therapeutics, LLC | $1,575.00 | 2022 | |
| Johnson & Johnson Health Care Systems INC. | $1,515.00 | 2022 | |
| Daiichi Sankyo INC. | $768.00 | 2022 | |
| Boston Scientific Corporation | $226.51 | 2025 | General - Therapies |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bowerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.